Cargando…
Drug-induced Liver Injury With Ritonavir-Boosted Nirmatrelvir: Evidence From Coronavirus Disease 2019 Emergency Use Authorization Adverse Event Reporting System
Autores principales: | Li, Guo-Fu, Yu, Guo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the AGA Institute.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937721/ https://www.ncbi.nlm.nih.gov/pubmed/36801390 http://dx.doi.org/10.1053/j.gastro.2023.02.008 |
Ejemplares similares
-
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022) -
Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023) -
Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
por: Li, Meng, et al.
Publicado: (2022) -
Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
por: Charness, Michael E., et al.
Publicado: (2022) -
Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023)